Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2037 participants.

Also called NCT01950819

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,037 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01950819
  • EudraCT 2013-000322-66
Other papers using this trial's data
  • Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation Journal of the American Society of Nephrology : JASN, 2018-07 DOI, PubMed 29752413, PMC6050928 Not in the PMC Open Access subset.
  • Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study Clinical transplantation, 2021-10 DOI, PubMed 34216395, PMC9255374 In the PMC Open Access subset under CC BY-NC.
  • Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019-11 DOI, PubMed 31152476
  • Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study Expert opinion on drug safety, 2020-10 DOI, PubMed 32633157

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Czechia, Egypt, France, Germany, Greece, India, Israel, Italy, Japan, Kuwait, Lebanon, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01950819. Randomized; no masking; primary purpose treatment. Start 2013-12-03 (actual); primary completion 2017-02-01 (actual). Results posted on 2019-01-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
Acronym
TRANSFORM
Condition
End Stage Renal Disease (ESRD)
Condition
Hemodialysis
Condition
Renal Replacement Therapy
Condition
Renal Transplantation
Intervention (Biological)
Induction therapy
Intervention (Drug)
Corticosteroids
Intervention (Drug)
EVR+rCNI
Intervention (Drug)
MPA+sCNI
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01950819
Content hash
d3e9459e99db3ffe10e38db568dc2ef5e3f70d3edaa223de46eaeebc4914f835